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Abstract
In the retina of mammals, dopamine (DA) is generally released by amacrine cells and is known to alter the physiology of most
retinal cells. It is well known that DA reduces the amplitude of the b-wave of the electroretinogram (ERG) in rabbit. However, the
speciﬁc receptor subtypes that mediate this action have not yet been elucidated. To do this, we recorded ﬂash ERGs before and after
the intravitreal injection of D1-like DA receptor agonists (SKF38393, A77693) and antagonist (SCH23390), and of D2-like agonist
(R()-propylnorapomorphine hydrochloride; NPA) and antagonist ((S)-()-sulpiride). Contralateral control eyes were injected
with the vehicle only. Both D1 agonists provoked a reduction of the ERG b-wave amplitude (34.0% and 59.2% of the pre-injection
level, respectively). The D2-like agonist NPA had no signiﬁcant eﬀects on ERG components. Unexpectedly, both D1- and D2-like
antagonists also reduced the b-wave amplitude (28.9% and 59.8%). Overall, these data suggest that the previously described eﬀect of
DA on the rabbit ERG b-wave came from activation of D1-like receptors. On the basis of the eﬀects observed with D2-like antag-
onist, a subtle contribution of D2-like presynaptic receptors cannot be ruled out.
 2004 Elsevier Ltd. All rights reserved.
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The retina of all mammals contains dopamine (DA).
In most cases, including rabbits, this catecholamine is
released by a sub-type of amacrine cells (Dowling &
Ehinger, 1978) which are generally located in the proxi-
mal part of the inner nuclear layer and ramify exten-
sively in one or more levels of the inner plexiform
layer (Mitrofanis, Vigny, & Stone, 1988). Five subtypes
of dopaminergic receptors have been described and des-
ignated D1 through D5. On the basis of their structure,0042-6989/$ - see front matter  2004 Elsevier Ltd. All rights reserved.
doi:10.1016/j.visres.2004.08.001
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E-mail address: christian.casanova@umontreal.ca (C. Casanova).binding properties, and intracellular action, these recep-
tors can be grouped into two subfamilies: (1) the D1-like
receptors (D1 and D5) which, when activated, stimulate
adenylyl cyclase activity and cAMP formation; (2) the
D2-like receptors (D2, D3, and D4) which inhibit aden-
ylyl cyclase. The activity of all neurons in the retina
can be modulated by DA because they all exhibit D1-,
D2-like or both receptor subfamilies. A number of stud-
ies have revealed the implication of DA in various forms
of retinal processing such as light adaptation (Marshak,
2001) and horizontal cell coupling (He, Weiler, &
Vaney, 2000). Because of the latter action, DA is
believed to modulate the center-surround antagonism
of retinal receptive ﬁelds (Bodis-Wollner, 1996; Bodis-
Wollner & Tzelepi, 1998; Boumghar, Marois, Jolicoeur,
& Casanova, 1997).
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administration of DA (Gottvall & Textorius, 2003;
Textorius, Nilsson, & Andersson, 1989) yields a reduc-
tion in the amplitude of the b-wave of the ﬂash electro-
retinogram (ERG) (Jagadeesh & Sanchez, 1981).
Comparable results were obtained after the i.v. injection
of apomorphine, which preferentially binds to D2-like
receptors (Gao et al., 1990). Our laboratory showed that
the acute administration of apomorphine could induce a
change in the contrast sensitivity of neurons in the lat-
eral geniculate nucleus, i.e., the main thalamic target
of ganglion cells (Boumghar et al., 1997). Conversely,
the destruction of the retinal DAergic network by the
neurotoxin 6-hydroxydopamine (6-OHDA), was shown
to increase the amplitude of the ERG b-wave (Lafond
et al., 1994; Olivier, Jolicoeur, Lafond, Drumheller, &
Brunette, 1986, 1987).
Despite the bulk of neuroanatomical and physiologi-
cal evidence showing that DA can modulate the activity
of retinal cells in mammals, very little is known about
the speciﬁc contribution of DA receptor subtypes in reti-
nal functioning. While the observation that apomor-
phine mimics the eﬀects of DA on the ERG suggests
that D2-like receptors may subtend the retinal physio-
logical impact of DA, the contribution of D1-like recep-
tors cannot be ruled out because they present,
depending of the enantiomer, substantial aﬃnity to apo-
morphine (Baldessarini, Kula, Zong, & Neumeyer,
1994; De Keyser, De Backer, Wilczak, & Herroelen,
1995). In the present study, we further investigated
in vivo the contribution of D1- and D2-like receptors
in the established DA-mediated reduction of the b-wave
amplitude in rabbits. Parts of these ﬁndings have been
presented in abstract form (Huppe´-Gourgues, Coude´,
& Casanova, 2002).2. Methods
2.1. Animal preparation
Experiments were carried out on 42 adult pigmented
rabbits (2.5–3.5 kg) that were provided by the Universite´
de Montre´al animal facilities. Animals were treated
according to the guidelines of the Canadian Council
on Animal Care. A 12 h light/dark cycle was used to
maintain the animals in a normal day–night cycle. All
procedures described below started in the morning to
minimize any inﬂuence of the circadian cycle. Atravet
(0.5 mgkg1) and atropine (0.1 mgkg1) were adminis-
trated to the animal 30 minutes before general anesthe-
sia that was induced by urethane (1.5 gkg1 i.v.)
(Sigma–Aldrich), administered via the marginal vein of
the ear. All surgical wounds and pressure points were in-
fused with a local anesthetic (Lidocaine hydrochloride
2%). Heart rate and O2 blood saturation were constantlymonitored with an oxymeter (Nonin). A tracheotomy
was performed. Deep tendon reﬂexes were checked to
ensure a satisfactory level of anesthesia during the sur-
gery. The animal was then placed in a stereotaxic frame
and muscular relaxation was obtained by injecting gall-
amine triethiodide (10 mgkg1h1, i.v.) mixed in dex-
trose ringer (5%). The animal was then artiﬁcially
ventilated (N2O/O2: 70/30% plus halothane 0.5–1%).
End-tidal CO2 level was maintained between 28 and 32
mmHg by adjusting the stroke volume and respiratory
rate. The electrocardiogram was continuously
monitored, and the core temperature was maintained
at 37–38 C by a feedback-controlled heating pad placed
under the animal. Pupils were dilated with isopto-atro-
pine (1%) and nictitating membranes were retracted with
local application of phenylephrine hydrochloride
(2.5%). The corneas were protected from desiccation
by applying artiﬁcial tears (carboxyl methylcellulose).
2.2. Recordings
ERG-Jet contact lens electrodes (Universo S.A.,
Switzerland) were placed on the cornea of the two eyes.
Two subdermal electrodes were positioned on the bridge
of the nose and between the ears on the top of the skull
and served as ground and reference, respectively. Given
that DAergic substances can have an eﬀect on pupil dila-
tion (e.g. Corbett, Buckley, & Richards, 1994) and that
the testing period lasted for several hours, artiﬁcial pu-
pils of 6 mm were used in some experiments. In these
cases, the ERG was recorded with a DTL ﬁber (He´bert,
Vaegan, & Lachapelle, 1999). No diﬀerences were noted
between the eﬀects of a given ligand on the ERG
whether artiﬁcial pupils or regular jet electrodes were
used. Moreover, casual observation of the pupil did
not reveal any signiﬁcant changes of its diameter during
the testing periods.
Signals were ampliﬁed 5000· (P511, Grass, WestWar-
wick, RI) and band-pass ﬁltered between 1 and 1000 Hz.
Signals were then fed to an analogue-digital interface
(1401plus, CED, Cambridge, UK) and were acquired
using the software Signal (v.2.0x, CED, Cambridge
UK). A custom loop program allowed us to record
ERGs at exactly 15 min apart for the whole duration
of the experimental procedure. To provide a more uni-
form stimulation (Ganzfeld-like stimulation) of the ret-
ina, ping-pong balls cut in half covered the eyes.
2.3. Visual stimulation
Visual stimulation consisted of a series of strobo-
scopic ﬂashes (single ﬂash duration of 10 ls) of diﬀerent
frequencies and intensities generated by a photic stimu-
lator PS33plus (Grass Instruments Co., West Warwick,
RI). The ﬂash lamp was placed 45 cm above the animals
head to allow for the simultaneous stimulation of the
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on the ERG were studied in the two luminance condi-
tions deﬁned in the ISECV standards (Marmor & Zren-
ner, 1998), and in a third intermediate condition. In
scotopic conditions, ﬂashes were presented at a fre-
quency (f) of 0.1 Hz, and at an intensity (i) of 0.1
cdm2 s, the background luminance (bl) being at 0
cdm2. In this condition, each ERG waveform repre-
sents an average of ﬁve responses. In photopic condi-
tions (i = 3 cdm2 s, bl = 30 cdm2), ﬂashes of 1 Hz
were used, and each ERG consisted of an average of
30 responses. In the intermediate condition in which
both rods and cones contribute to vision (namely mes-
opic), parameters were set at: f = 0.5 Hz, i = 2 cdm2 s
and bl = 13 cdm2. Background illumination corre-
sponded to the room illumination by tungsten lamps
(3200 K). Responses were averaged 15 times. All lumi-
nance values were obtained at the level of the animals
eye with a photometer.
2.4. Dopaminergic agents
The active substances used to characterize the contri-
bution of D1-like receptor subtypes were the agonists
(±)-SKF-38393 hydrochloride [(±)-1-phenyl-2,3,4,5-
tetrahydro-(1H)-3-benzazepine-7,8-diol hydrochloride;
Sigma] and A-77636 hydrochloride [()-(1R,3S)-3-
adamantyl-1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-
1H-2-benzopyran hydrochloride; RBI-Sigma], and the
antagonist R(+)-SCH-23390 hydrochloride [R(+)-7-
chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-
1H-3- benzazepine hydrochloride]. The involvement of
D2 receptors was assessed by administering the agonist
R()-propylnorapomorphine hydrochloride [R()-10,
11-dihydroxy-N-n-propylnoraporphine hydrochloride;
(NPA) Sigma], and the antagonist, (S)-()-sulpiride,
[(S)-5-aminosulfonyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-
2-methoxybenzamide; Sigma]. For clarity, the terms
SKF-38393, A-77636, SCH-23390, NPA, and sulpiride
will be used throughout. The ligands were dissolved in
sterile water, with the exception of sulpiride which was
dissolved in 0.1 N HCl. Concentrations used varied
from 1 to 0.00001 mg in the injection volume of 100
ll. All solutions had a pH of 7, with the exception
of sulpuride-HCl and HCl-vehicle solutions for which
the pH was 1.5 in both cases. Injections were made
in the vitreous humor i.e., a volume of 1.4 ml; (Green,
Leopold, & Sawyer, 1957) by inserting a 30G needle
(Becton Dickinson and Co, Franklin Lakes, NJ) at-
tached to a 250 ll Hamilton syringe throughout the
sclera, 2–3 mm caudal to the limbus.
2.5. Experimental protocol
After a 1 h period of adaptation to the lightning con-
ditions, binocular ERGs were recorded every 15 min fora control period of 2 h. This was done to determine
baseline amplitude of the ERG components of the two
eyes (normalized response). The DAergic agent was then
injected intravitreally into the test eye (T0), and vehicle
(i.e., sterile water in all cases, except for Sulpiride exper-
iments, in which the HCl solution was used) was injected
into the control eye. Recordings were then made every
15 min after the injection. Flashes were interrupted be-
tween each recording session, and the animal was kept
in the background illumination condition used in the gi-
ven protocol. In general, recordings lasted 5 h after the
drug administration, but could be prolonged up to 24 h.
In general, after recovery, a second injection protocol
was initiated with the same animal, in identical lighting
conditions. The former control eye was then used as the
test eye, and vice-versa, and the same drug was injected.
Therefore the n values provided throughout represent
the actual number of injections.
Once the last recording was made, the animal was
killed with an i.v. injection of about 1.5 ml of pentobar-
bital sodium (Euthanyl 110 mgkg1). Eyeballs were re-
moved and dissected for a gross evaluation of any
trauma resulting from the injection procedure, and par-
ticularly to verify that no structure (e.g. lens) was inad-
vertently nicked by the needle.
We measured time-to-peak and amplitude just be-
fore, and at predetermined time intervals after, the injec-
tion of test agents. Post-injection b-wave amplitudes
were expressed as percent of pre-injection amplitudes.
In addition, the amplitude computed at each hour
post-injection was statistically compared to that re-
corded from the control eye. The b-wave of the latter
was never signiﬁcantly modiﬁed throughout the record-
ing session. Statistical signiﬁcance ( p 6 0.05) was deter-
mined with paired t-test, oneway ANOVA for
parametric data and Kruskall–Wallis and Wilcoxon test
for non-parametric data.3. Results
3.1. D1-like receptor contribution to the b-wave amplitude
The intravitreal injection of the D1-like agonist
SKF38393 reduced the amplitude of the ERG signal.
A representative example is shown in Fig. 1.
SKF38393 reduced the b-wave amplitude by 30%, while
the latency of the waveform remained constant at
82.3 ± 0.3 ms (panel A, upper traces). The vehicle alone
did not modify the ERG of the control eye (bottom
traces). Panel B represents the time course of the action
of the agonist. The maximal SKF38393-induced reduc-
tion was observed between 1 and 2 h post-injection. A
recovery was apparent 4 h after injection and was vir-
tually completed after 7 h (see also the upper-right



































































Fig. 1. (A) Representative example of ERGs before and after the
intravitreal injection of D1-like receptors agonist, SKF38393 at 1
mg(100 ll)1 (top traces) in scotopic condition. There is a reduction of
about 30% of the b-wave amplitude. A total recovery was observed 7 h
post-injection. Injection of sterile water in the contralateral eye failed
to modify the ERG waveform (bottom traces). (B) Response proﬁle of
the SKF38393 action on the ERG b-wave amplitude as a function of
time. Arrows indicate the time at which the ERGs presented in panel A
were selected. The vertical dotted line represents the injection time. (C)
Results from twenty-four injections of SKF38393 (1 mg(100 ll)1) and
of the vehicle were pooled together and normalized. A signiﬁcant
decrease was observed during 2 h post-injection. One hundred percent
level represents the mean amplitude before injection. Error bars
represent SEM. In this and all ﬁgures: * = p < 0.1, ** = p < 0.05,
*** = p < 0.001.
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control eye throughout the recording period. Pooled
data from 24 SKF38393 injections were normalized
and results are shown in panel C of Fig. 1 (a signiﬁcant
eﬀect was observed in 23 out of the 24 injections. In
this and all subsequent cases, data from all injections
were used for statistical analysis). The maximum inhib-
itory eﬀect of the DA agonist was observed 2 h post-
injection, with a mean reduction of 34.0% ± 4.1%
(tpaired = 3.66, p = 0.001). The diﬀerence in b-wave
amplitude between SKF38393 and control eyes
returned to control values 7 h post-injection (tpaired =
1.94, p = 0.06). The action of SKF38393
(1 mg(100 ll)1) on the ERG b-wave was comparable
in all conditions of illumination (oneway ANOVA,
f(22,2) = 1.51, p = 0.24). The reduction of the b-wave
amplitude was 26.8% ± 8.0% (n = 6), 45% ± 6.8%
(n = 10), and 34.6 ± 5.1% (n = 9) in photopic, mesopic,
and scotopic conditions, respectively.
Two SKF38393 doses were used in the study, 0.1 and
1 mg(100 ll)1. When compared to the vehicle, the low
concentration yielded a mean decrease of 20.3% ± 6.1%
(n = 6) of the b-wave amplitude, while the high concen-
tration led to a reduction of 34.0% ± 4.1% (n = 24).
Even if only two doses were studied, the eﬀect of
SKF38393 appears to be dose-dependent since a higher
concentration of the agonist yielded a more pronounced
reduction of the b-wave (Kruskal–Wallis, p = 0.0001).
Only the 1 mg (100 ll)1 dose produced an eﬀect that
was statistically signiﬁcant (tpaired = 3.66, p = 0.001).
The D1-like receptor agonist A77636 had a stronger
eﬀect on the b-wave than SKF38393. Three represent-
ative examples are shown in Fig. 2. Panel A presents
the eﬀect of A77636 at a dose of 1 mg(100 ll)1 in
the mesopic lighting condition (ﬁlled symbol). The
agonist considerably reduced the b-wave amplitude 8
h post-injection (decrease of 60% from pre-injection
recordings), whereas the vehicle had no eﬀect in the
control eye (open symbol). As illustrated, no recovery
of the b-wave was observed at this dose of A77636.
This observation stands for all ﬁve injections made at
1 mg despite the fact that post-injection recordings
lasted up to 18 h. In all ﬁve cases the b-wave decrease
was signiﬁcant (Wilcoxon, p = 0.043) 2 h after the drug
administration, and reached a value of 60.3 ± 4.6%
after 10 h. Panel B shows the action of A77636 admin-
istered at 0.5 mg(100 ll)1. In this case, the reduction
of the b-wave was of 51.0% after 3 h. When consider-
ing all four injections at this dose, A77636 produced a
reduction of 43.0% ± 6.5% of the b-wave amplitude
after 3 h. Two out of four injections recovered after
10 h, the two others failed to recover. Finally,
A77636 was injected at a low concentration of 0.2
mg(100 ll)1 in one animal (n = 2). In both cases,
the agonist failed to modify the amplitude of the
























































Fig. 3. (A) Eﬀects of the D1-like receptor antagonist SCH23390
(1 mg(100 ll)1). The injection of this ligand (n = 6) caused a
signiﬁcant reduction of b-wave amplitude from 2 to 6 h post-injection.
Results from six injections in mesopic condition were pooled. (B) Eﬀect
of the injection of the D2-like receptor antagonist sulpiride 1 mg(100
ll)1 (n = 8) in the mesopic condition. The ligand produced a
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Fig. 2. Eﬀects of the administration of the D1-like agonist A77636 at
diﬀerent doses in mesopic condition. (A) 1 mg(100 ll)1; (B) 0.5
mg(100 ll)1; 0.2 mg(100 ll)1. Only the ﬁrst two doses yielded a
decrease of the ERG b-wave. Results in panels A–C come from three
animals.
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SCH23390 (1 mg(100 ll)1) also produced a reduction
of 28.9% ± 8.8% of the b-wave amplitude 3 h post-injec-
tion in the mesopic condition (panel A of Fig. 3). The
amplitude of the b-wave was signiﬁcantly diﬀerent from
that of the control eye 1 h after injection (Wilcoxon,
p = 0.028) and the reduction in signal amplitude lasted
for the next 6 h. A signiﬁcant eﬀect of SCH23390 on
the b-wave amplitude was observed in four out of six
injections.3.2. D2-like receptor contribution to b-wave amplitude
Injections of the D2-like receptor agonist NPA failed
to produce any signiﬁcant changes in the b-wave ampli-
tude. Panel A of Fig. 4 shows the outcome of twelve injec-tions: clearly, there was no signiﬁcant diﬀerence between
the b-wave amplitude of the NPA-treated and normal eye
up to 10 h after the injections. Increasing or decreasing
the NPA concentration yielded comparable ﬁndings. This
is illustrated in panel B of Fig. 4. Varying the dose from
0.0001 to 1 mg(100 ll)1 failed to produce any signiﬁcant
changes in the waveform amplitude (1 mg(100 ll)1,
mean reduction of the b-wave 27% ± 1.8%, n = 9; 0.1
mg(100 ll)1, 20.4 ± 6.5%, n = 8; 0.01 mg(100 ll)1,
16.7%, n = 1; 0.001 mg(100 ll)1, 22.0 ± 1.6%, n = 4;
0.0001 mg(100 ll)1, 0.08 ± 1.8%, n = 3) (Kruskal–
Wallis, p = 0.12). Similarly, changing the background
luminance did not reveal any notable physiological im-
pact of NPA (Kruskal–Wallis, p = 0.73). The numbers
of injections of NPA 1mg(100 ll)1 in the photopic, mes-








































Fig. 4. (A) Injection of the D2-like receptor agonist Norpropylapo-
morphine (NPA) (1 mg(100 ll)1) failed to modify the b-wave
amplitude. Number of injections was 9. (B) Eﬀect of various
concentrations of NPA (1 to 0.0001 mg(100 ll)1) on the b-wave.
Doses greater than 0.0001 mg(100 ll)1 tended to reduce the ERG.
However, no dose was found to produce a signiﬁcant change of the
waveform amplitude. The number of injections is shown at the top of
each bar. Error bars represent SEM.
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antagonist sulpiride was administered (panel B of Fig. 3).
This ligand reduced the b-wave amplitude for more than
15 h. The maximum eﬀect was seen 6 h post-injection and
the b-wave amplitude was reduced to 59.8 ± 4.6% of the
original amplitude (Wilcoxon, p = 0.018).4. Discussion
The present ﬁndings indicate that retinal activity, as
measured with the b-wave of the electroretinogram, is
mainly modulated by the activation of D1-like ratherthan D2-like receptors. There was no relationship be-
tween the observed changes and the various luminance
conditions in which the testing was done, suggesting that
the eﬀective ligands studied here were not speciﬁc to the
rod or cone pathways of the retina.
The D1-like receptor agonists SKF38393 and
A77636 produced a signiﬁcant reduction in the ampli-
tude of the b-wave, but not of the a-wave (data not
shown). A similar modulation of the ERG was re-
ported by Textorius et al. (1989) who demonstrated
that DA provoked a decrease of the ERG b-wave in
a rabbit in vivo eye cup preparation. Comparable ﬁnd-
ings were described after the systemic administration of
apomorphine in the same animal model (Jagadeesh &
Sanchez, 1981). To our knowledge, only one study pre-
viously investigated the impact of SKF38393 on retinal
evoked potentials. In rabbits, Marmor et al. (1988) re-
ported that an intramuscular injection SKF38393 had
very little inhibitory eﬀect on the b-wave amplitude
and oscillatory potentials. The fact that they observed
a more subtle eﬀect than ours is likely due to the diﬀer-
ence in the mode of administration of the ligand (intra-
muscular vs. intravitreal). We are not aware of any
study reporting the eﬀect of the agonist A77636 on reti-
nal function. On the basis of its long-lasting action on
the b-wave amplitude, this ligand appears to be more
potent then SKF 38393 at similar doses. Our ﬁndings
that D1-like agonist can modulate the amplitude of
the ERG b-wave are further substantiated by the
observation that, in monkey, the administration of
the D1-like agonist cy208-243 reduces the pattern
ERG at low spatial frequencies (Peppe, Antal, Tagliati,
Stanzione, & Bodis-Wollner, 1998). The mechanisms
by which the D1-like agonists used in the present study
aﬀect the ERG remain to be determined. It is generally
accepted that the b-wave reﬂects the K+-mediated
depolarization of Mu¨ller cells (Newman & Odette,
1984; Wen & Oakley, 1990; Xu & Karwoski, 1994)
even though there is mounting evidence that depolariz-
ing ON bipolar cells may also directly contribute to the
waveform (Green & Kapousta-Bruneau, 1999; Stock-
ton & Slaughter, 1989). Both cell types contain D1-like
receptors (Nguyen-Legros et al., 1987; Nguyen-Legros,
Simon, Caille, & Bloch, 1997; Veruki & Wa¨ssle, 1996)
and may therefore contribute to the eﬀects of the D1-
like agonists.
While the administration of D1-like agonists induced
a decrease of the ERG b-wave, the D2-like agonist stud-
ied here (R()-NPA; aﬃnity 100- to 425-fold greater
than for D1-like receptors, Baldessarini et al., 1994;
Gao et al., 1990) failed to produce a signiﬁcant change
in the amplitude of the ERG. This is somewhat surpris-
ing given that apomorphine, a D2-like agonist, is known
to reduce the amplitude of the ERG b-wave. Recent
studies showed that apomorphine has a greater aﬃnity
for D2 than D1-like receptors 2.6- to 22-fold depending
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tissue studied (Baldessarini et al., 1994; De Keyser et al.,
1995; Gao et al., 1990). One explanation would be that,
in the retina, apomorphine binds preferentially to D1-
like receptors. Another explanation would be that
NPA may not target receptors coupled with b-wave
mechanisms. This latter suggestion is however unlikely
because Mu¨ller cells, which are implicated in b-wave
genesis, possess D2 receptors (Biedermann, Frohlich,
Grosche, Wagner, & Reichenbach, 1995; in the guinea
pig retina). If present in rabbits, it is possible that acti-
vation of these receptors yielded subtle changes that
may not be seen at the level of a gross retinal response
such as the ERG, or simply that NPA acts on D2-like
receptors other than the kind Mu¨ller cells express (e.g.
D4). Another possibility may come from the fact that
the presynaptic autoreceptors are of the D2-like type.
Activation of the autoreceptors would reduce the syn-
thesis and release of the endogenous DA which normally
binds to both D1- and D2-like receptors (Stanzione et al.,
1999), thus masking any strong eﬀect of the ligand. NPA
could have a dual action, inhibiting DA-release through
the D2-like autoreceptors but simultaneously activating
b-wave reduction through postsynaptic D1-like recep-
tors. Although not statistically signiﬁcant, the reduction
in b-wave amplitude by NPA at all but the lowest dose
(Fig. 4B) is consistent with the last assumption, i.e. the
D2-like eﬀect outweighing the D1-like eﬀect.
Overall, given the high aﬃnity of the DA agonists
SKF38393 and A77636 that we used for the D1-like
receptors (150- and 30- to 750-fold greater for D1-like
receptors, respectively; Kebabian et al., 1992; Seeman
& Van Tol, 1994), the results of the present study
strongly suggest that the eﬀect of DA on the ERG de-
scribed by Jagadeesh and Sanchez (1981) and Textorius
et al. (1989) was most likely mediated through activation
of D1-like receptors.
The intravitreal injection of the D1-like antagonist
SCH23390 (aﬃnity: 5500-fold; (Seeman & Van Tol,
1994)) produced a signiﬁcant reduction of the b-wave
amplitude, but less pronounced than that induced by
the agonist SKF38393. This result was unexpected. In-
deed, blocking the D1-like receptors should yield a
reduction of the sites available for DA, therefore mim-
icking a decrease of DA content. This decrease would
then yield an increase of the b-wave amplitude (Lafond
et al., 1994; Olivier et al., 1986; Olivier et al., 1987).
Marmor et al. (1988) found the same contradictory ef-
fect in rabbits as they reported that the intramuscular
injection of both SCH23390 and SKF38393 reduced1 Note that the enantiomer of apomorphine used by Jagadeesh and
Sanchez (1981) was not speciﬁed in their article.the b-wave amplitude. Other laboratories also found
that D1 antagonists can modulate retinal responses.
Wioland, Rudolf, and Bonaventure (1990) showed that
haloperidol, a mixed D1- and D2-like antagonist, re-
duced the b-wave amplitude of the chicken retina in
photopic condition. In the isolated, arterially perfused
eye of the cat, the D1-like antagonist ﬂuphenazine
provoked an opposite eﬀect, i.e. an enhancement of
the b-wave (Schneider & Zrenner, 1991). In the present
study, SCH23390 was administered at a single dose of
1 mg(100 ll)1. It may be possible that at this dose,
the ligand exhibits some neurotoxicity. This assumption
however can hardly be reconciled with the fact that there
was a recovery of the ERG waveform following the
antagonists administration. Another option is that
SCH23390 exerted its action via non-DA receptors.
For example, it has been reported that NPA not only
has aﬃnity for D1- and D2-like receptors but also for al-
pha-2 adrenoreceptors (Baldessarini et al., 1994).
Clearly, the mechanisms by which SCH23390 can mod-
ify the retinal function remain to be determined.
While the D2-like agonist NPA had no signiﬁcant ef-
fect on the ERG, the antagonist S-sulpiride (aﬃnity
3000-fold for D2-compared to D1-like receptors, (See-
man & Van Tol, 1994)) provoked a long-lasting reduc-
tion of the b-wave amplitude. Again, other studies
revealed that D2-like antagonists can alter retinal physi-
ology. In rabbits, Jagadeesh, Lee, and Salazar-Booka-
man (1980) reported that the intravenous injection of
chlorpromazine increased the amplitude of the b-wave.
This eﬀect is opposite to that described in the present
study. It may be due to diﬀerences in the mode of admin-
istration or in the speciﬁcity of the two agents at diﬀerent
receptor subtypes. In cats, the administration of sulpiride
induced an increase of the b-wave amplitude in scotopic
conditions (Schneider & Zrenner, 1991). This is contrary
to our ﬁndings and the diﬀerence may again come from
inter-species diﬀerences or from the distinct experimental
approach (in vivo vs. isolated eye preparation). It is pos-
sible that the reduction of b-wave amplitude that was ob-
served here after the administration of sulpiride may be
mediated through the DA autoreceptors. Blocking the
presynaptic autoreceptors could raise the synthesis and
release of the endogenous DA, and the released DA
could then activate both postsynaptic D1- and D2-like
receptors.
In conclusion, our data further support the involve-
ment of DA in the modulation of retinal function. They
showed that the dopaminergic impact on the ERG
b-wave is largely mediated by D1-like receptors, suggest-
ing that the latter are preferentially involved in the
transmission of information within the inner and middle
parts of the retina. Since none of the agonists used here
has an exclusive aﬃnity for D1- or D2-like receptors, and
that D2-like antagonist can alter the amplitude of the
b-wave, we cannot rule out any subtle contribution of
144 F. Huppe´-Gourgues et al. / Vision Research 45 (2005) 137–145D2-like receptors in the dopaminergic modulation of the
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